5,253 reports of this reaction
6.1% of all ISOTRETINOIN reports
#2 most reported adverse reaction
INFLAMMATORY BOWEL DISEASE is the #2 most commonly reported adverse reaction for ISOTRETINOIN, manufactured by JG Pharma Inc.. There are 5,253 FDA adverse event reports linking ISOTRETINOIN to INFLAMMATORY BOWEL DISEASE. This represents approximately 6.1% of all 86,016 adverse event reports for this drug.
Patients taking ISOTRETINOIN who experience inflammatory bowel disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFLAMMATORY BOWEL DISEASE is moderately reported among ISOTRETINOIN users, representing a notable but not dominant share of adverse events.
In addition to inflammatory bowel disease, the following adverse reactions have been reported for ISOTRETINOIN:
INFLAMMATORY BOWEL DISEASE has been reported as an adverse event in 5,253 FDA reports for ISOTRETINOIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFLAMMATORY BOWEL DISEASE accounts for approximately 6.1% of all adverse event reports for ISOTRETINOIN, making it one of the most commonly reported side effect.
If you experience inflammatory bowel disease while taking ISOTRETINOIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.